Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal phase ll/lll trial evaluating efficacy of QBM-001 for the treatment of young children with a rare autistic spectrum disorder

Trial Profile

A pivotal phase ll/lll trial evaluating efficacy of QBM-001 for the treatment of young children with a rare autistic spectrum disorder

Planning
Phase of Trial: Phase II/III

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs QBM-001 (Primary)
  • Indications Pervasive child development disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Q BioMed
  • Most Recent Events

    • 12 Dec 2018 According to a Q BioMed media release, the company has announced a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of QBM-001, in support of Q BioMed's Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children, including this trial which is expected to start in 2019.
    • 09 Oct 2018 According to a Q BioMed media release, the company has visited many potential trial sites in the U.S. and Europe in preparation for this trial.
    • 01 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top